Advaxis, Inc. and FusionVax Sign a Memorandum of Understanding for the License of Advaxis' ADXS-HPV in Asia
4/22/2013 12:56:04 PM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS) (“Advaxis” or the “Company”), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has entered into a Memorandum of Understanding (MoU) with FusionVax, Inc. (“FusionVax”) setting forth the main terms under which Advaxis will, subject to the entry of a definitive agreement, exclusively license its lead clinical stage product candidate, ADXS-HPV, to FusionVax for Asia.
Help employers find you! Check out all the jobs and post your resume.
comments powered by